A Phase 1 Study of ZN-c3 as a Single Agent in Subjects with Solid Tumors
This is a Phase 1/2 open-label, multicenter study, evaluating the safety, tolerability, efficacy, pharmacokinetics (PK) and pharmacodynamics of ZN-c3 alone and in combination with other drugs.
Primary Dose Escalation:
To investigate the safety and tolerability of single agent ZN-c3, including identification of the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D).
Primary Dose Expansion:
To investigate the clinical activity of WEE1 inhibition by ZN-c3 at RP2D based on Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 in subjects with uterine serous carcinoma and subjects with mutations of interest.
To obtain preliminary estimates of antitumor efficacy of single agent ZN-c3.
To investigate the plasma pharmacokinetics (PK) of single agent ZN-c3.
Any of the following treatment interventions within the specified time frame prior to Cycle 1 Day 1:
Major surgery within 28 days.
Any chemotherapy within 21 days or 5 half-lives
Radiation therapy within 21 days; however, if the radiation portal covered > Autologous or allogeneic stem cell transplant within 3 months.
Current use of any other investigational drug therapy within 28 days or 5 half lives (whichever is shorter).
Inability to discontinue treatment with prescription or non-prescription drugs, or to discontinue consumption of food and herbal supplements that are strongand moderate CYP3A inhibitors and inducers or P-gp inhibitors at least 14 days prior to Cycle 1 Day 1.
A serious illness or medical condition(s) including, but not limited to, the following:
a. Brain metastases that require immediate treatment or are clinically or radiologically unstable (ie, have been stable for > Unresolved toxicity of Grade >1 attributed to any prior therapies (excluding ≤Grade 2 neuropathy, alopecia, or skin pigmentation).
Prior therapy with ZN-c3 or known hypersensitivity to any drugs similar to ZN-c3 in class or any inactive ingredients present in ZN-c3 (see Pharmacy Manual).
Prior therapy with a WEE1 inhibitor.
Pregnant or lactating females or females of childbearing potential who have a positive serum pregnancy test within 14 days prior to Cycle 1 Day 1.
Patients with active (uncontrolled, metastatic) second malignancies or requiring therapy.
Individuals who are judged by the Investigator to be unsuitable as study subjects.
12-lead ECG demonstrating a corrected QT interval using Fridericia's formula (QTcF) of >470 msec, except for subjects with atrioventricular pacemakers or other conditions (eg, right bundle branch block) that render the QT measurement invalid.
History or current evidence of congenital or family history of long QT syndrome or Torsade de Pointes (TdP).
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.
Moffitt Cancer Center is committed to the health and safety of our patients and their families. For more information on how we’re protecting our new and existing patients, visit our COVID-19 Info Hub